中新网北京3月15日电(韦香惠)生物医药产业作为关乎国民健康的重要领域，始终受到国家的高度重视。今年政府工作报告中，创新药首次被纳入，并明确提出要开辟生命科学等新赛道，显示了我国在生物医药领域加速发展的决心。
在近日的一场对话中，资深业内人士史录文就中国创新药面临的挑战与机遇发表了独到见解。他指出，随着全球生物技术的飞速发展，中国生物医药产业正迎来前所未有的发展机遇。然而，要想实现创新药的加速发展，仍需在多个方面进行突破。
首先，创新药的研发需要更多的资金支持和政策引导。史录文认为，政府应加大对生物医药企业的扶持力度，通过税收优惠、资金补贴等方式，降低企业的研发成本，鼓励企业加大研发投入。
其次，创新药研发的关键在于人才的培养和引进。史录文强调，要吸引和培养一批具有国际视野的高水平研发人才，为创新药的研发提供智力支持。同时，还需要建立和完善创新药的知识产权保护体系，保护研发者的合法权益，激发创新活力。
最后，史录文提出，应加快创新药的审评审批速度，优化审评流程，缩短上市时间，使更多的创新药能够及时惠及患者。
史录文的观点为我国创新药的发展提供了宝贵的建议。随着政府工作报告的发布，我们有理由相信，在政策的支持和全行业的共同努力下，中国创新药将迎来新的发展春天。
英文标题：《China’s Push to Speed Up and Breakthrough in Innovative Drug Development》
英文关键词：Innovative Drugs, Biopharmaceuticals, New Frontier
英文新闻内容：China’s biopharmaceutical industry, a crucial sector for national health, is gaining increased attention from the government. This year’s government work report for the first time included innovative drugs as a priority, highlighting the commitment to opening new frontiers in life sciences.
In a recent dialogue, industry veteran Shi Luwen shared his insights on the challenges and opportunities facing China’s innovative drug development. He noted that with the rapid global advancement of biotechnology, China’s biopharmaceutical industry is poised for unprecedented growth. However, to accelerate the development of innovative drugs, breakthroughs are needed in several areas.
Firstly, more financial support and policy guidance are required to fund biopharmaceutical research. Shi advocates for increased government subsidies and tax incentives to reduce R&D costs and encourage higher R&D investments from enterprises.
Secondly, the key to innovative drug development lies in the cultivation and attraction of talent. He emphasizes the importance of nurturing a pool of international-standard researchers to drive innovation. Furthermore, strengthening the protection of intellectual property rights for innovative drugs is essential to safeguarding the rights of researchers and fostering innovation.
Lastly, Shi suggests streamlining the review and approval process for innovative drugs to expedite their market availability, ensuring that more patients can benefit from these breakthrough treatments in a timely manner.
Shi’s perspectives offer valuable insights into the future of China’s innovative drug industry. With the government’s policy support and collective efforts across the industry, China’s innovative drugs are poised to enter a new phase of development.
【来源】http://www.chinanews.com/gn/2024/03-15/10180452.shtml
Views: 1